Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

Sections

Sort by
Page 1 of 62

  1. Content type: Research article

    The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enric...

    Authors: Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola and Alessandra Cesano

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:63

    Published on:

  2. Content type: Research article

    Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes. NK cells and T-lymphocytes mediate early kill...

    Authors: Jay Friedman, Megan Morisada, Lillian Sun, Ellen C. Moore, Michelle Padget, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro and Clint T. Allen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:59

    Published on:

  3. Content type: Research article

    Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor n...

    Authors: Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:61

    Published on:

  5. Content type: Short report

    Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the...

    Authors: Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell and Carolina S. Ilkow

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:62

    Published on:

  6. Content type: Case report

    Sebaceous carcinoma is an aggressive adnexal skin tumor with a predilection for the eyelids and sebaceous glands of the head and neck.

    Authors: Evidio Domingo-Musibay, Paari Murugan, Alessio Giubellino, Sandeep Sharma, Daniel Steinberger, Jianling Yuan, Matthew A. Hunt, Emil Lou and Jeffrey S. Miller

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:58

    Published on:

  7. Content type: Review article

    Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer the...

    Authors: Robert D. Leone and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:57

    Published on:

  8. Content type: Review

    During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific ...

    Authors: Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll and Michael S. von Bergwelt-Baildon

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:56

    Published on:

  9. Content type: Research article

    Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation ...

    Authors: Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang and Keith Dredge

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:54

    Published on:

  10. Content type: Case report

    The treatment options for metastatic malignant melanoma have drastically changed recently,including the increased use of immunotherapeutic agents that offer significant responses. Accordingly, it hasbecome com...

    Authors: Joseph I. Clark, Shams Bufalino, Shruti Singh and Ewa Borys

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:53

    Published on:

  11. Content type: Research article

    Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytot...

    Authors: Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy and Len W. Seymour

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:55

    Published on:

  12. Content type: Case report

    Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Never...

    Authors: Léa Paolini, Caroline Poli, Simon Blanchard, Thierry Urban, Anne Croué, Marie-Christine Rousselet, Sarah Le Roux, Nathalie Labarrière, Pascale Jeannin and José Hureaux

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:52

    Published on:

  13. Content type: Research article

    Corticosteroids are routinely utilized to alleviate edema in patients with intracranial lesions and are first-line agents to combat immune-related adverse events (irAEs) that arise with immune checkpoint block...

    Authors: Amber J. Giles, Marsha-Kay N. D. Hutchinson, Heather M. Sonnemann, Jinkyu Jung, Peter E. Fecci, Nivedita M. Ratnam, Wei Zhang, Hua Song, Rolanda Bailey, Dionne Davis, Caitlin M. Reid, Deric M. Park and Mark R. Gilbert

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:51

    Published on:

  14. Content type: Research article

    The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor t...

    Authors: Edwin R. Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G. Swisher, William N. William Jr, Jiexin Zhang, Jack Lee, Tina Cascone, John V. Heymach, Marie-Andrée Forget, Cara Haymaker, Chantale Bernatchez, Neda Kalhor, Annikka Weissferdt…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:48

    Published on:

  15. Content type: Hypothesis

    Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of indivi...

    Authors: Tolga Turan, Deepti Kannan, Maulik Patel, J. Matthew Barnes, Sonia G. Tanlimco, Rongze Lu, Kyle Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter Hendrickx, Alessandra Cesano, Lisa H. Butterfield, Howard L. Kaufman, Thomas J. Hudson, Davide Bedognetti, Francesco Marincola…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:50

    Published on:

  17. Content type: Review

    Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to ...

    Authors: Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar and Richard Tuli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:46

    Published on:

  18. Content type: Research article

    TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ’s immune suppressive effects has become of ...

    Authors: Rikke B. Holmgaard, David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:47

    Published on:

  19. Content type: Correction

    Unfortunately, after publication of this article [1], it was noticed that corrections to the legends of Figs. 1 and 2 were not correctly incorporated. The correct legends can be seen below.

    Authors: Yiwen Li, Carmine Carpenito, George Wang, David Surguladze, Amelie Forest, Maria Malabunga, Mary Murphy, Yiwei Zhang, Andreas Sonyi, Darin Chin, Douglas Burtrum, Ivan Inigo, Anthony Pennello, Leyi Shen, Laurent Malherbe, Xinlei Chen…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:45

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:31

  20. Content type: Position article and guidelines

    Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs ...

    Authors: Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:44

    Published on:

  21. Content type: Case report

    Patients with metastatic Merkel cell carcinoma (mMCC) who experience disease progression on immunotherapy have limited additional standard options. Given evidence of synergism between radiation therapy (RT) an...

    Authors: Melody J. Xu, Susan Wu, Adil I. Daud, Siegrid S. Yu and Sue S. Yom

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:43

    Published on:

  22. Content type: Research article

    Extrapulmonary small cell carcinomas (ESCC) are rare but aggressive tumors. Relapses are common despite treatment with chemotherapy and/or radiotherapy. Prospective data for treatment of ESCC are lacking; trea...

    Authors: Mohammed Salhab, Yazan Migdady, Melanie Donahue, Yiqin Xiong, Karen Dresser, William Walsh, Benjamin J. Chen and James Liebmann

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:42

    Published on:

  23. Content type: Research article

    Adoptive cell transfer (ACT) is a promising cancer immunotherapeutic strategy that remains ineffective for a large subset of patients. ACT with memory CD8+ T cells (Tmem) has been shown to have superior efficacy ...

    Authors: Amanda Contreras, Megan V. Beems, Andrew J. Tatar, Siddhartha Sen, Prakrithi Srinand, M. Suresh, Tahra K. Luther and Clifford S. Cho

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:41

    Published on:

  24. Content type: Research article

    Immune checkpoint inhibiting antibodies were introduced into routine clinical practice for cancer patients. Checkpoint blockade has led to durable remissions in some patients, but may also induce immune-relate...

    Authors: Heinz Läubli, Catharina Balmelli, Lukas Kaufmann, Michal Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat Müller, Oliver Gautschi, Frank Stenner, Alfred Zippelius, Adrian Egli and Sacha I. Rothschild

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:40

    Published on:

  25. Content type: Research article

    Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patie...

    Authors: Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack, Rachel Lubong Sabado, Russell Berman, Richard Shapiro, Hsin-Hui Huang, Iman Osman, Nina Bhardwaj and Anna C. Pavlick

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:38

    Published on:

Page 1 of 62
Submit a manuscript

Follow

2017 Journal Metrics

Advertisement

Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426

Contact us